 SAN DIEGO, Oct. 7, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Companys investigational KRASG12C inhibitor, with Sanofis investigational SHP2 inhibitor SAR442720, also known as RMC-4630. The Phase 12 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer NSCLC and KRASG12C mutations. 